Erin Hertlein
Overview
Explore the profile of Erin Hertlein including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
1119
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Stiff A, Fornerod M, Kain B, Nicolet D, Kelly B, Miller K, et al.
Nat Genet
. 2024 Oct;
56(11):2434-2446.
PMID: 39367245
Genomic profiles and prognostic biomarkers in patients with acute myeloid leukemia (AML) from ancestry-diverse populations are underexplored. We analyzed the exomes and transcriptomes of 100 patients with AML with genomically...
2.
Jeremy E, Artiga E, Elgamal S, Cheney C, Eicher D, Zalponik K, et al.
Blood Adv
. 2024 Sep;
9(1):1-14.
PMID: 39348689
Acute myeloid leukemia (AML) is the most common and lethal leukemia in adults. AML consists of many genetic subtypes, which limits broad applicability of targeted therapy. We discovered that the...
3.
Fobare S, Sharpe C, Quinn K, Bryant K, Miles L, Bowman R, et al.
bioRxiv
. 2024 Sep;
PMID: 39345464
Mutations in protein tyrosine phosphatase non-receptor type 11 ( ) have been considered late acquired mutations in acute myeloid leukemia (AML) development. To interrogate the ontogeny of mutations, we utilized...
4.
Elgamal O, Fobare S, Vibhute S, Mehmood A, Vroom D, Johnson M, et al.
JCI Insight
. 2024 Apr;
9(8).
PMID: 38646934
Acute myeloid leukemia (AML) is a fatal disease characterized by the accumulation of undifferentiated myeloblasts, and agents that promote differentiation have been effective in this disease but are not curative....
5.
Fobare S, Elgamal O, Wunderlich M, Stahl E, Mehmood A, Furby C, et al.
Cancers (Basel)
. 2024 Feb;
16(3).
PMID: 38339323
Background: Acute myeloid leukemia (AML) is the malignant proliferation of immature myeloid cells characterized by a block in differentiation. As such, novel therapeutic strategies to promote the differentiation of immature...
6.
Abdul-Aziz A, Devine R, Lyberger J, Chang H, Kovacs A, Lerma J, et al.
Cells
. 2023 Aug;
12(16).
PMID: 37626855
Cellular senescence is a durable cell cycle arrest as a result of the finite proliferative capacity of cells. Senescence responds to both intrinsic and extrinsic cellular stresses, such as aging,...
7.
Eisenmann E, Stromatt J, Fobare S, Huang K, Buelow D, Orwick S, et al.
Cancers (Basel)
. 2023 Jan;
15(1).
PMID: 36612026
Acute myeloid leukemia (AML) with mutations in the tumor suppressor gene TP53 confers a dismal prognosis with 3-year overall survival of <5%. While inhibition of kinases involved in cell cycle...
8.
Fobare S, Kohlschmidt J, Ozer H, Mrozek K, Nicolet D, Mims A, et al.
Blood Adv
. 2021 Nov;
6(5):1371-1380.
PMID: 34847232
Prognostic factors associated with chemotherapy outcomes in patients with acute myeloid leukemia (AML) are extensively reported, and one gene whose mutation is recognized as conferring resistance to several newer targeted...
9.
Goswami S, Mani R, Nunes J, Chiang C, Zapolnik K, Hu E, et al.
Blood
. 2021 Nov;
139(9):1340-1358.
PMID: 34788382
Dysregulated cellular differentiation is a hallmark of acute leukemogenesis. Phosphatases are widely suppressed in cancers but have not been traditionally associated with differentiation. In this study, we found that the...
10.
Chen T, Harrington B, Truxall J, Wasmuth R, Prouty A, Sloan S, et al.
J Hematol Oncol
. 2021 Feb;
14(1):36.
PMID: 33627156
B-cell receptor (BCR) antagonists such as the BTK inhibitor ibrutinib have proven to effectively target chronic lymphocytic leukemia (CLL) tumor cells, leading to impressive response rates in these patients. However...